- Adragos Pharma has completed the acquisition of Sanofi’s commercial-scale sterile fill-finish facility in Maisons-Alfort, France.
- The site adds large-scale pre-filled syringe, vial, and lyophilized injectable manufacturing capacity to Adragos’ European CDMO network.
Adragos Pharma has completed the acquisition of a commercial-scale sterile fill-finish facility in Maisons-Alfort, France, from Sanofi, expanding its contract manufacturing capabilities in Europe. The site, located in the south-eastern suburbs of Paris, manufactures sterile injectables including pre-filled syringes, liquid vials, and lyophilized products.
The Maisons-Alfort facility is regularly audited by international health authorities, including ANSM, NMPA, MFDS, and ANVISA, and supports the global supply of injectable medicines. Employees from the site will join Adragos Pharma as part of the transaction, ensuring operational continuity and retaining expertise in sterile manufacturing.
The acquisition adds high-volume pre-filled syringe capacity to Adragos’ existing network, which includes vial and ampoule filling operations in Switzerland and France. The expanded platform strengthens the company’s position in sterile injectables CDMO services across Europe.
“Maisons-Alfort is a landmark acquisition for Adragos and a defining step in our growth journey. We are adding one of Europe’s leading sterile manufacturing sites to our network. Our ambition is clear: to invest, scale, and further develop the site into a top-tier fill-finish platform.”
Dr. Andreas Raabe, Founder and CEO of Adragos Pharma
The transaction aligns with Adragos Pharma’s strategy to expand pharmaceutical manufacturing capacity and meet demand for sterile injectables through its contract manufacturing platform.
